Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)

Trial Profile

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESONATE-2
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 03 Jun 2019 According to a Janssen Pharmaceuticals media release, data from this study will be presented in full during an oral presentation at the 24th European Hematology Association (EHA) Congress (Amsterdam, 14th Jun 2019, abstract S107).
    • 03 Jun 2019 Results from five-year follow-up of ibrutinib monotherapy in patients with previously untreated chronic lymphocytic leukaemia presented in a Janssen Pharmaceuticals media release.
    • 28 Feb 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top